复发难治性霍奇金淋巴瘤抗PD-1治疗失败后化疗或化疗联合抗PD-1的疗效:Lysa中心系列研究
该回顾性研究评估了30例复发难治性霍奇金淋巴瘤患者抗PD-1治疗后疗效不佳的挽救治疗方案。24例进展患者中,17例单用化疗(组1),7例化疗联合抗PD-1(组2);24例中16例(67%)获得客观缓解。中位随访12.1个月,化疗开始后中位PFS为11个月,中位OS未达到。
要点
- 抗PD-1治疗后进展的24例中,16例(67%)获得客观缓解。
- 化疗开始后中位PFS为11个月(95%CI 6.3至未达到),中位OS未达到。
- 6例缓解患者后续接受异基因造血干细胞移植。
核心结论
- 在高度经治的霍奇金淋巴瘤患者中,这些观察结果提示抗PD-1治疗可能使肿瘤细胞对化疗重新敏感。
研究设计与样本
- 回顾性研究,纳入30例复发或难治性霍奇金淋巴瘤患者,评估抗PD-1治疗后疗效不佳的挽救治疗。
- 抗PD-1治疗前70%接受过自体干细胞移植,93%接受过维布妥昔单抗(BV)。
- 抗PD-1治疗后疗效不佳定义为进展(PD,n=24)和部分缓解(PR,n=6)。
主要发现
- 24例PD患者中,17例单用化疗(组1),7例化疗联合抗PD-1(组2);24例中16例(67%)获得客观缓解。
- 15例接受相同化疗方案的患者中,12例获得PR或CR。
- 组1:7例CR(41%)、3例PR(18%)、7例PD(41%);组2:4例CR(57%)、2例PR(29%)、1例SD(14%)。
- 24例PD患者中位抗PD-1相关PFS为7.5个月(95%CI 5.7-11.6)。
- 未观察到意外毒性;6例缓解患者后续接受异基因干细胞移植。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-PD-1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV), but median progression free survival (PFS) is only one year. The efficacy of treatment following anti-PD-1 is not well known. We retrospectively investigated the efficacy of salvage therapies for unsatisfactory response to anti-PD-1 therapy, assessed by PET-CT according to the Lugano criteria, in 30 R/R HL patients. Patients were highly pre-treated before anti-PD-1 (70% received ASCT and 93% BV). Unsatisfactory responses to anti-PD1 therapy were progressive disease (PD) (n=24) and partial response (PR) (n=6). For the 24 PD patients, median anti-PD-1 related PFS was 7.5 months (95%CI, 5.7-11.6); 17 received subsequent CT alone (Group 1) and 7 received CT in addition to anti-PD-1 (Group 2). 16/24 patients (67%) obtained an objective response. In the 15 patients treated with the same CT, twelve obtained PR or complete response (CR). In Group 1, there were 7 CR (41%), 3 PR (18%), and 7 PD (41%). In Group 2, there were 4 CR (57%), 2 PR (29%), and 1 SD (14%). No unexpected toxicity was observed. Six patients who achieved response proceeded to allogeneic SCT. With a median follow-up of 12.1 months (7-14.7), the median PFS following the initiation of CT was 11 months (95%CI, 6.3; not reached) and the median of overall survival was not reached. These observations in highly pre-treated HL patients suggest that anti-PD-1 therapy might re-sensitize tumor cells to CT. This article is protected by copyright. All rights reserved.
引用
- Rossi C, Gilhodes J, Maerevoet M, et al. Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers. Am J Hematol. 2018. PMID: 29884994. doi:10.1002/ajh.25154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。